Cardiovascular autonomic neuropathy in the course of diabetes â the review of actual knowledge.

Authors

  • Beata Kieć-Wilk University Hospital in Krakow, Department of Metabolic Diseases, Medical College Jagiellonian University, Kraków, Poland
  • Joanna Gastol University Hospital in Krakow, Department of Metabolic Diseases, Medical College Jagiellonian University, Kraków, Poland
  • Lukasz Pawlinski University Hospital in Krakow, Department of Metabolic Diseases, Medical College Jagiellonian University, Kraków, Poland

DOI:

https://doi.org/10.18388/pb.2019_287

Abstract

Diabetic neuropathy, including autonomic cardiovascular neuropathy, is the most common chronic complication of diabetes. It causes serious health and social consequences, leading to a significant reduction of life expectancy in DM patients. Its development is initially asymptomatic and therefore often underestimated, and only the early detection of diabetic neuropathy gives a real chance to stop its progression and prevent irreversible damage to the nerves. The optimal glycemic control is the most important factor preventing the development of neuropathy, inhibiting its occurrence and progression. In the advanced stage, however, only symptomatic treatment remains.

The article provides an overview of current knowledge about etiopathogenesis, therapy, symptoms and the latest clinical trials on NSN and DM.

Downloads

Download data is not yet available.

Published

2019-12-30

Issue

Section

Articles